Gero.AI, a biotech company developing therapeutics informed by large-scale human data and AI modelling, has appointed an Advisor to enhance medicinal chemistry capability across its discovery programs.
The Advisor is supporting Gero.AI’s scientific leadership in refining hit selection and optimization workflows, including how initial compounds are evaluated for potency and molecular properties, and how those properties are improved to enable favourable pharmacokinetics.
This guidance strengthens Gero.AI’s ability to translate computational insights into high-quality drug candidates and accelerate progression toward the clinic.
